Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: Results of a pilot safety study in rhesus macaques using anti-programed death-ligand 1 (Avelumab)

AIDS

Volumn 30, Issue 16, 2016, Pages 2487-2493

  Gill, Amanda L ^a   Green, Samantha A ^a   Abdullah, Shahed ^b   Le Saout, Cecile ^a   Pittaluga, Stefania ^b   Chen, Hui ^a   Turnier, Refika ^c   Lifson, Jeffrey ^c   Godin, Steven ^d   Qin, Jing ^a   Sneller, Michael C ^a   Cuillerot, Jean Marie ^e   Sabzevari, Helen ^f   Clifford Lane, H ^a   Catalfamo, Marta ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d Smithers Viscient   (United States)

^e EMD SERONO INC   (United States)

^f EMD Serono Inc ^*  (United States)

Author keywords

Anti programed death ligand 1 immunotherapy; HIV; HIV immunotherapy; Programed death 1; Programed death ligand 1

Indexed keywords

AVELUMAB; PROGRAMMED DEATH 1 LIGAND 1; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LYMPH NODE; LYMPH NODE BIOPSY; MACROPHAGE; NONHUMAN; PHENOTYPE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS LOAD; ADVERSE DRUG REACTION; ANIMAL; PATHOLOGY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; B7-H1 ANTIGEN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HIV INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; LYMPH NODES; MACACA MULATTA; PILOT PROJECTS; PROGRAMMED CELL DEATH 1 RECEPTOR; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; TREATMENT OUTCOME;

EID: 84982845649     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001217     Document Type: Article

References (44)

1. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191:1499-1512.
2. Reignat S, Webster GJ, Brown D, Ogg GS, King A, Seneviratne SL, et al. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med 2002; 195:1089-1101.
3. Hersperger AR, Migueles SA, Betts MR, Connors M. Qualitative features of the HIV-specific CD8R T-cell response associated with immunologic control. Curr Opin HIV AIDS 2011; 6:169-173.
4. Quigley M, Pereyra F, Nilsson B, Porichis F, Fonseca C, Eichbaum Q, et al. Transcriptional analysis of HIV-specific CD8R T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med 2010; 16:1147-1151.
5. Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol 2015; 36:265-276.
6. Pombo C, Wherry EJ, Gostick E, Price DA, Betts MR. Elevated expression of CD160 and 2B4 defines a cytolytic HIV-specific CD8R T-cell population in elite controllers. J Infect Dis 2015; 212:1376-1386.
7. Petrovas C, Price DA, Mattapallil J, Ambrozak DR, Geldmacher C, Cecchinato V, et al. SIV-specific CD8R T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection. Blood 2007; 110:928-936.
8. Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, Adams WC, et al. PD-1 is a regulator of virus-specific CD8R T cell survival in HIV infection. J Exp Med 2006; 203:2281-2292.
9. Kuchroo VK, Anderson AC, Petrovas C. Coinhibitory receptors and CD8 T cell exhaustion in chronic infections. Curr Opin HIV AIDS 2014; 9:439-445.
10. Peretz Y, He Z, Shi Y, Yassine-Diab B, Goulet JP, Bordi R, et al. CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction. PLoS Pathog 2012; 8:e1002840.
11. El-Far M, Halwani R, Said E, Trautmann L, Doroudchi M, Janbazian L, et al. T-cell exhaustion in HIV infection. Curr HIV/AIDS Rep 2008; 5:13-19.
12. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009; 458:206-210.
13. Titanji K, Velu V, Chennareddi L, Vijay-Kumar M, Gewirtz AT, Freeman GJ, et al. Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques. J Clin Invest 2010; 120:3878-3890.
14. Finnefrock AC, Tang A, Li F, Freed DC, Feng M, Cox KS, et al. PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination. J Immunol 2009; 182:980-987.
15. Dyavar Shetty R, Velu V, Titanji K, Bosinger SE, Freeman GJ, Silvestri G, et al. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J Clin Invest 2012; 122:1712-1716.
16. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443:350-354.
17. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, et al. Upregulation of PD-1 expression on HIVspecific CD8R T cells leads to reversible immune dysfunction. Nat Med 2006; 12:1198-1202.
18. Trabattoni D, Saresella M, Biasin M, Boasso A, Piacentini L, Ferrante P, et al. B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood 2003; 101:2514-2520.
19. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26:677-704.
20. Eppihimer MJ, Gunn J, Freeman GJ, Greenfield EA, Chernova T, Erickson J, et al. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation 2002; 9:133-145.
21. Schreiner B, Mitsdoerffer M, Kieseier BC, Chen L, Hartung HP, Weller M, et al. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol 2004; 155:172-182.
22. Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, Park YM, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett 2006; 580:755-762.
23. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad SciUS A 2003; 100:5336-5341.
24. Sheppard KA, Fitz LJ, Lee JM, Benander C, George JA, Wooters J, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett 2004; 574:37-41.
25. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 2004; 173:945-954.
26. Riley JL. PD-1 signaling in primary T cells. Immunol Rev 2009; 229:114-125.
27. Zinselmeyer BH, Heydari S, Sacristan C, Nayak D, Cammer M, Herz J, et al. PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J Exp Med 2013; 210:757-774.
28. Dong H, Strome SE, Matteson EL, Moder KG, Flies DB, Zhu G, et al. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest 2003; 111:363-370.
29. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27:111-122.
30. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362:355-358.
31. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993; 362:359-362.
32. Connick E, Mattila T, Folkvord JM, Schlichtemeier R, Meditz AL, Ray MG, et al. CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue. J Immunol 2007; 178:6975-6983.
33. Fukazawa Y, Park H, Cameron MJ, Lefebvre F, Lum R, Coombes N, et al. Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med 2012; 18:1673-1681.
34. Cubas RA, Mudd JC, Savoye AL, Perreau M, van Grevenynghe J, Metcalf T, et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med 2013; 19:494-499.
35. Perreau M, Savoye AL, De Crignis E, Corpataux JM, Cubas R, Haddad EK, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med 2013; 210:143-156.
36. Sneller MC, Kopp WC, Engelke KJ, Yovandich JL, Creekmore SP, Waldmann TA, et al. IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8R T effector memory population in peripheral blood. Blood 2011; 118:6845-6848.
37. Petrovas C, Yamamoto T, Gerner MY, Boswell KL, Wloka K, Smith EC, et al. CD4 T follicular helper cell dynamics during SIV infection. J Clin Invest 2012; 122:3281-3294.
38. Yamamoto T, Price DA, Casazza JP, Ferrari G, Nason M, Chattopadhyay PK, et al. Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8R T-cell exhaustion in HIV infection. Blood 2011; 117:4805-4815.
39. Demers KR, Reuter MA, Betts MR. CD8(R) T-cell effector function and transcriptional regulation during HIV pathogenesis. Immunol Rev 2013; 254:190-206.
40. Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, Weeks KA, et al. Lytic granule loading of CD8R T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008; 29:1009-1021.
41. Rosignoli G, Cranage A, Burton C, Nelson M, Steel A, Gazzard B, et al. Expression of PD-L1, a marker of disease status, is not reduced by HAART in aviraemic patients. AIDS 2007; 21:1379-1381.
42. Cockerham LR, Jain V, Sinclair E, Glidden DV, Hartogenesis W, Hatano H, et al. Programmed death-1 expression on CD4(R) and CD8(R) T cells in treated and untreated HIV disease. AIDS 2014; 28:1749-1758.
43. Mason SW, Sanisetty S, Osuna-Gutierrez C, Lim S-Y, Chaniewski S, Campellone S, et al. Viral suppression was induced by anti-PD-L1 following ARV-interruption in SIV-infected monkeys. CROI 2014; 2014.
44. Eron JJ, Gay C, Bosch R, Ritz J, Hataye JM, Hwang C, et al. Safety, immunologic and virologic activity of anti-PD-L1 in HIV-1 participants on ART.CROI 2016; 2016.